EA200301221A1 - Лечение расстройств с гиперактивностью и дефицитом внимания - Google Patents

Лечение расстройств с гиперактивностью и дефицитом внимания

Info

Publication number
EA200301221A1
EA200301221A1 EA200301221A EA200301221A EA200301221A1 EA 200301221 A1 EA200301221 A1 EA 200301221A1 EA 200301221 A EA200301221 A EA 200301221A EA 200301221 A EA200301221 A EA 200301221A EA 200301221 A1 EA200301221 A1 EA 200301221A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hyperactivity
disorders
treatment
attention
deficiency
Prior art date
Application number
EA200301221A
Other languages
English (en)
Inventor
Клаус Петер Хертель
Йерн Арнт
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of EA200301221A1 publication Critical patent/EA200301221A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Recrystallisation Techniques (AREA)

Abstract

Применение 3-[1-[2-(1-ацетил-2,3-дигидро-1H-индол-3-ил)этил]-1,2,3,6-тетрагидропиридин-4-ил]-6-хлор-1H-индол, любого из его энантиомеров и его фармацевтически приемлемых солей для получения фармацевтической композиции для лечения расстройств с гиперактивностью и дефицитом внимания.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200301221A 2001-05-09 2002-05-07 Лечение расстройств с гиперактивностью и дефицитом внимания EA200301221A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100732 2001-05-09
PCT/DK2002/000298 WO2002089797A1 (en) 2001-05-09 2002-05-07 Treatment of adhd

Publications (1)

Publication Number Publication Date
EA200301221A1 true EA200301221A1 (ru) 2004-04-29

Family

ID=8160484

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200301221A EA200301221A1 (ru) 2001-05-09 2002-05-07 Лечение расстройств с гиперактивностью и дефицитом внимания

Country Status (23)

Country Link
US (1) US7294638B2 (ru)
EP (1) EP1387682A1 (ru)
JP (1) JP2004528361A (ru)
KR (1) KR20040007544A (ru)
CN (1) CN1507351A (ru)
AR (1) AR033287A1 (ru)
BG (1) BG108400A (ru)
BR (1) BR0209443A (ru)
CA (1) CA2446652A1 (ru)
CO (1) CO5540378A2 (ru)
CZ (1) CZ20033197A3 (ru)
EA (1) EA200301221A1 (ru)
HR (1) HRP20030852A2 (ru)
HU (1) HUP0400075A2 (ru)
IL (1) IL158413A0 (ru)
IS (1) IS6992A (ru)
MX (1) MXPA03010136A (ru)
NO (1) NO20034972L (ru)
NZ (1) NZ528896A (ru)
PL (1) PL367778A1 (ru)
SK (1) SK15002003A3 (ru)
WO (1) WO2002089797A1 (ru)
ZA (1) ZA200307955B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003102097A1 (en) * 2002-05-31 2003-12-11 H. Lundbeck A/S The hydrochloride of (s)-(+)-3-[1-[2-(1-acetyl-2,3-dihydro-1h-indol-3-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-6-chloro-1h-indole
AU2005299706A1 (en) * 2004-10-22 2006-05-04 Froimowitz, Mark Methylphenidate analogs and methods of use thereof
EP2288362A4 (en) * 2008-04-19 2012-05-02 Nisarga Biotech Pvt Ltd PLANT-BASED COMPOSITION FOR DECREASING ADD / L ADHD, AND METHOD THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
ZA9711376B (en) * 1996-12-20 1998-07-21 Lundbeck & Co As H Indole or dihydroindole derivatives
AU2002230665A1 (en) * 2000-12-06 2002-06-18 Sepracor, Inc. 4,4-disubstituted piperidines for use as dopamine, serotonin and norepinephrine ligands

Also Published As

Publication number Publication date
US20040152737A1 (en) 2004-08-05
ZA200307955B (en) 2004-10-13
WO2002089797A8 (en) 2004-03-25
NZ528896A (en) 2004-12-24
PL367778A1 (en) 2005-03-07
IS6992A (is) 2003-10-13
SK15002003A3 (sk) 2004-05-04
US7294638B2 (en) 2007-11-13
WO2002089797A1 (en) 2002-11-14
CO5540378A2 (es) 2005-07-29
BG108400A (bg) 2004-11-30
EP1387682A1 (en) 2004-02-11
CA2446652A1 (en) 2002-11-14
JP2004528361A (ja) 2004-09-16
NO20034972D0 (no) 2003-11-07
KR20040007544A (ko) 2004-01-24
HUP0400075A2 (hu) 2004-04-28
BR0209443A (pt) 2004-08-03
CZ20033197A3 (en) 2004-06-16
NO20034972L (no) 2003-11-07
MXPA03010136A (es) 2004-03-10
HRP20030852A2 (en) 2005-06-30
AR033287A1 (es) 2003-12-10
IL158413A0 (en) 2004-05-12
CN1507351A (zh) 2004-06-23

Similar Documents

Publication Publication Date Title
ATE454378T1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
ATE449081T1 (de) Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE294800T1 (de) N-(5-(((5-alkyl-2-oxazolyl)methyl)thio)-2- thiazolyl)-carboxamide als inhibitoren cyclinabhängiger kinasen
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
TR200102969T2 (tr) Siklik protein tirozin kinaz önleyicileri.
RS52653B (en) INDOLINON DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROSE DISEASES
SG164283A1 (en) New benzimidazole derivatives
DK1458713T3 (da) Indolinonderivater anvendelige som proteinkinaseinhibitorer
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
YU4903A (sh) N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
CY1107383T1 (el) Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
MY136767A (en) Formulations comprising an indolinone compound
SE9903997D0 (sv) New compounds
YU88103A (sh) Lecenje adhd
ATE546452T1 (de) Pyrazolopyrrolderivate als proteinkinaseinhibitoren
DK1268472T3 (da) 3-aminopyrazolinhibitorer af cyclinafhængige kinaser
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
EA200301221A1 (ru) Лечение расстройств с гиперактивностью и дефицитом внимания
ATE337320T1 (de) Indolderivate als pde5-inhibitoren
MXPA04000775A (es) Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables.